CSL Ltd said on Tuesday the fees it pays people to donate blood plasma, the core ingredient of its treatments, were stabilising after COVID-19 movement restrictions forced the Australian biomedical ...

CSL is one of three tier one plasma therapy companies who benefit from an oligopoly in this highly consolidated market. All the players are vertically integrated as plasma sourcing is the most ...

Australian biomedical giant CSL Ltd on Wednesday reported a 6% drop in annual profit as collections of plasma, the key ingredient of its treatments, were subdued in the first half and hit sales of ...